Vasoactive intestinal polypeptide tied to migrane attacks, Finds JAMA Study

Patients were randomly allocated to receive a 2-hour infusion of vasoactive intestinal polypeptide or placebo on 2 different days. The primary end point was the difference in incidence of experimentally induced migraine attacks during the observational period (0-12 hours) between vasoactive intestinal polypeptide and placebo.

The following findings were observed-

5. a.Twenty-one patients (17 [81%] women and 4 [19%] men; mean [range] age, 25.9 [19-40] years) were recruited in the study.
6. b.Fifteen patients (71%; 95% CI, 48%-89%) developed migraine attacks after vasoactive intestinal polypeptide compared with 1 patient (5%; 95% CI, 0%-24%) who developed a migraine attack after placebo (P < .001).
7. c.The VIP-induced migraine attacks mimicked patients' spontaneous attacks.
8. d.The area under the curve (AUC) of headache intensity scores (0-12 hours), as well as the AUC of the superficial temporal artery diameter (0-180 minute) were significantly greater after vasoactive intestinal polypeptide compared with placebo.

Therefore, it was concluded that a 2-hour infusion of vasoactive intestinal polypeptide caused migraine attacks, suggesting an important role of vasoactive intestinal polypeptide in migraine pathophysiology. Vasoactive intestinal polypeptide and its receptors could be potential targets for novel migraine drugs.

Pellesi L, Al-Karagholi MA, De Icco R, et al. Effect of Vasoactive Intestinal Polypeptide on Development of Migraine Headaches: A Randomized Clinical Trial. JAMA Netw Open. 2021;4(8):e2118543. doi:10.1001/jamanetworkopen.2021.18543